Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 5/20 | 0.60 |
| ▸ | PTGES | O14684 | 2/20 | 0.58 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.56 |
| ▸ | LDHA | P00338 | 1/20 | 0.51 |
| ▸ | HPGDS | O60760 | 2/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13850790 | 0.91 | P4HTM (0.52) | P4HTMPTGESBAZ2BLDHAHPGDS | |
| SCHEMBL13850954 | 0.86 | P4HTM (0.70) | P4HTMPTGESBAZ2BHPGDSPTGS2 | |
| SCHEMBL979262 | 0.83 | PTGES (0.72) | PTGES | |
| SCHEMBL979857 | 0.82 | PTGES (0.57) | P4HTMPTGESHDAC1PTGS2PTGS1 | |
| SCHEMBL979230 | 0.79 | P4HTM (0.47) | P4HTMPTGES | |
| SCHEMBL13850948 | 0.79 | PTGES (0.54) | P4HTMPTGESPTGS2EGFR | |
| SCHEMBL981457 | 0.79 | PTGES (0.74) | P4HTMPTGES | |
| SCHEMBL13850953 | 0.79 | PTGES (0.51) | P4HTMPTGESPTGS2EGFR | |
| SCHEMBL977653 | 0.78 | PTGES (0.52) | P4HTMPTGESPTGS2PTGS1EGFR | |
| SCHEMBL13850884 | 0.77 | PTGES (0.54) | P4HTMPTGESHDAC1PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | PTGER1, CYP3A5, SULT1E1 | P4HTM 377/4885PTGES 9/4885BAZ2B 4513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.